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Introduction
Coronary artery bypass grafting (CABG) represents
the most common surgical procedure in the treatment
of ischemic heart disease offering good results in terms
of survival and quality of life. After the standardization
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Background. Indirect revascularization is a therapeutic approach
in case of severe angina not suitable for percutaneous or surgical reva-
scularization. Transmyocardial revascularization (TMR) is one of the
techniques used for indirect revascularization and it allows to create
transmyocardial channels by a laser energy bundle delivered on left ven-
tricular epicardial surface. Benefits of the procedure are related mainly
to the angiogenesis caused by inflammation and secondly to the de-
struction of the nervous fibers of the heart. 
Patients and method. From September 1996 up to July 1997, 14
patients (9 males – 66.7%, mean age 64.8±7.9 years) underwent
TMR. All patients referred angina at rest; Canadian Angina Class was
IV in 7 patients (58.3%), III in 5 (41.7%). Before the enrollment, co-
ronarography was routinely performed to find out the feasibility of  Co-
ronary Artery Bypass Graft (CABG): 13 patients (91,6%) had coro-
nary arteries lesions not suitable for direct revascularization; this con-
dition was limited only to postero-lateral area in one patient submitted
to combined TMR + CABG procedures.
Results. Mean discharge time was 3,2±1,3 days after surgery. All
patients were discharged in good clinical conditions. Perfusion thallium
scintigraphy was performed in 7 patients at a mean follow-up of 4±2
months, showing in all but one an improvement of perfusion defects.
Moreover an exercise treadmill improvement was observed in the same
patients and all of them are in good clinical conditions, with signifi-
cantly reduced use of active drugs. 
Conclusion. Our experience confirms that TMR is a safe and fea-
sible procedure and it offers a therapeutic solution in case of untreata-
ble angina. Moreover, it could be a hybrid approach for patients un-
dergoing CABGs in case of absence of vessels suitable for surgical ap-
proach in limited areas of the heart.
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Background.  La rivascolarizzazione miocardica indiretta è un
approccio terapeutico in caso di angina severa non idonea alla rivasco-
larizzazione diretta percutanea o chirurgica. La rivascolarizzazione
miocardica mediante  laser (TMR) è una delle tecniche utilizzate per
la rivascolarizzazione indiretta e permette di creare canali transmio-
cardici attraverso un fascio di energia laser irradiato sulla superficie
epicardica del ventricolo sinistro. I meccanismi attraverso cui la TMR
può determinare una riduzione dell’angina sono correlati principal-
mente all’angiogenesi indotta dalla infiammazione e in secondo luogo
alla distruzione delle fibre nervose.
Pazienti e metodi. Da settembre 1996 fino a luglio 1997, 14 pa-
zienti (9 maschi - 66,7%, età media 64,8 ± 7,9 anni) sono stati sot-
toposti a TMR. Tutti i pazienti erano sintomatici per angina, 7
(58,3%) con Canadian Angina Class IV e 5 (41,7%) con classe III.
Tutti i pazienti sono stati valutati pre-operatoriamente mediante stu-
dio coronarografico. Tredici pazienti (91,6%) avevano lesioni corona-
riche non idonee alla rivascolarizzazione diretta. In un paziente è sta-
to confezionato un by-pass sulla parete postero-laterale oltre alla TMR.
Risultati. Il tempo medio di degenza postoperatoria è stato di 3,2
± 1,3 giorni. Tutti i pazienti sono stati dimessi in buone condizioni cli-
niche. La scintigrafia al tallio è stata eseguita in 7 pazienti dopo un fol-
low-up medio di 4,0 ± 2,0 mesi: in tutti i casi, tranne uno, è stato evi-
denziato un miglioramento della perfusione miocardica con netto mi-
glioramento allo sforzo sul tapis roulant e netta riduzione della neces-
sità di assunzione di farmaci vasoattivi.
Conclusioni. La nostra esperienza conferma che laTMR è una
procedura sicura e fattibile e offre una soluzione terapeutica in caso di
angina intrattabile. Inoltre, potrebbe essere un approccio ibrido per i
pazienti sottoposti a CABG qualora in aree limitate del cuore non vi
siano coronarie adatte alla rivascolarizzazione chirurgica.
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of the technique by Effler and Favaloro in 1968, many
patients received  CABG procedure with progressive re-
duction of the operative risk due to improvement of sur-
gical treatment. 
The discussion about the management of patients with
angina and coronary artery lesions not suitable for per-
cutaneous or surgical treatment, is still ongoing and many
strategies of indirect myocardial revascularization have
been proposed with variable results. On the basis of the
old techniques, many authors have been interested in the
debate regarding indirect revascularization. Large expe-
riences of indirect revascularization have been conducted
using transmyocardial revascularization (TMR) that al-
lows to create transmyocardial channels by a laser ener-
gy bundle delivered on left ventricular epicardial surface.
According to the original hypothesis, benefits of the pro-
cedure are related mainly to the angiogenesis caused by
inflammation and secondly to the destruction of the nerv-
ous fibers of the heart.  
Patients and methods
We present our previous experience carried out more than ten
years ago at our institution. From September 1996 up to July 1997,
14 patients (9 males – 66.7%, mean age 64.8±7.9 years) underwent
TMR. All patients referred angina at rest; Canadian Angina Class was
IV in 7 patients (58.3%), III in 5 (41.7%). All the patients enrolled
were under treatment with 3 to 4 vasoactive drugs (nitrates, B-block-
ers, calcium antagonist, Ace inibitors). Heparin and iv nitroglycerin
were administered in 9 patients because of their highly unstable con-
ditions.
All the patients had previous acute myocardial infarction
(AMI). Six patients (50%) had previously been submitted to direct
myocardial revascularization: CABGs (4 patients.) or PTCA (2 pa-
tients.), performed about 5.8±4.5 years before. 2 of the 4 patients
already submitted to CABG, underwent stenotic graft PTCA after
3.9±3.2 years. Preoperative mean ejection fraction was 51±9%.
Risk factors were smoke (7/12), hypertension (9/12), dislypidemia
(5/12), diabetes (4/12), familiarity (5/12), obesity (3/12), renal fail-
ure (3/12), peripheral arteriopathy involving carotid arteries. Before
the enrollment, coronarography was routinely performed to find out
the feasibility of CABG. In 13 patients (91,6%) had coronary arteries
lesions not suitable for direct revascularization; this condition was
limited only to postero-lateral area in 1 patient submitted to com-
bined TMR + CABG procedures. All the patients were evaluated with
preoperative scintigraphy: decision for surgical treatment depended
on the evidence of ischemia in the areas not suitable for conventional
revascularization in patient with intractable angina. 
Before to start the laser procedure, Intra Aortic Balloon Pump
(IABP) was implanted in 6 patients because of their unstable he-
modynamic conditions. The device was removed 36 hours later; no
complication due to IABP were reported. The mean duration of the
surgical procedure was 3.17±0.7 hours with a “lasing” time of
34.5±12.8 minutes. The mean number of channels performed were
38.6±9.5 per patient. During the procedure, autotransfusion was
never needed. Some runs of ventricular tachiarrhythmia were evi-
dent in the most unstable cases; 3 patients experienced ventricular
fibrillation during the surgery requiring a 30 Joules cardiac shock.
In 2 cases an adjunctive defibrillation was done in the ICU in the
early post-operative period. The mean bleeding was 325±150 cc dur-
ing the first 24 hours and 2 units of autologous blood were neces-
sary in two cases.
Surgical technique
The patient position on the operative table is supine but with
a gentle right rotation of the trunk and the left arm suspended over
the head. A general anesthesia and a standard intubation is then per-
formed. In highly risk patients, an IABP is positioned through the
femoral artery before starting the laser procedure. Through a small
skin incision (6-7 cm) at the IV or V intercostal space, antero-lat-
eral wall of the left ventricle was exposed. The IV space is the best
way to treat the basal areas of the heart but the V is preferable for
the inferior and apical areas.
After heart exposure a xylocaine infusion is started to reduce the
risks of ventricular arrhythmia. A number of channels are then per-
formed through the left ventricular wall treating the areas preopera-
tively mapped by scintigraphy. The system used is a Holmium source
Laser whose energy bundle is administered by a flexible fiberoptic, 1
mm diameter. The laser energy is delivered in short pulses of 250 µsec.
that progressively achieve a complete transmyocardial channel using
an average power of 6 watts. The blood suffusion, that generally ap-
pears after the myocardial perforation, is easily controlled by a sponge
and a gentle digit compression for few minutes. By transesophageal
echo steam-like bubbles are visualized as a result of tissue ablation at
endocardial surface, assessing the completeness of the channel. A tem-
porary pacemaker wire is positioned before the thoracic closure in the
usual manner. The intercostal nerve alcoholization or a catheter po-
sitioning for analgesic infusion can be also easily done to reduce the
pain that generally can appear after a thoracotomy.
Results 
No inotropic drugs were administered during the In-
tensive Care Unit (ICU) stay, except for 1 patient who
needed 5 micrograms/kg/min of dobutamine in the first
period. All patients received a corticosteroid treatment
for at least 38 hours. CPK maximum level was 1200±230
but CPK-MB was 81±40, resulting statistically signifi-
cant in pts with IABP implanted (p<0.05). ECG alter-
ation have not been observed, except 1 patient who ex-
perienced perioperative acute AMI. We had one death
in a 80-years-old male, after 10 days from the operation
because of pulmonary failure who required a tra-
cheostomy and resulting in a fatal complication.
Mean discharge time was 3,2±1,3 days after surgery.
All patients were discharged in good clinical conditions.
Perfusion thallium scintigraphy was performed in 7
patients at a mean follow-up of 24,0±2,0 months, show-
ing in all but one an improvement of perfusion defects.
Moreover an exercise treadmill improvement was observed
in the same patients and all of them had significantly re-
duced use of active drugs. 
Discussion
Patients with severe diffuse coronary artery disease and
refractory angina that cannot be treated with conventional
coronary artery bypass graft surgery or angioplasty
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may be candidates for transmyocardial laser revascular-
ization therapy. Recent randomized studies on TMR have
demonstrated relief of angina (1-3) but the cause of these
beneficial effects is unclear. It has been proposed that
TMR may increase myocardial perfusion by promoting
angiogenesis (4). Other studies have shown that TMR
causes myocardial denervation (5). 
Many experiences suggest that TMR is an effective
short-term therapy for the relief of angina and the im-
provement of the quality of life of patients with diffuse
coronary artery disease who cannot receive angioplasty
or bypass graft surgery. Unfortunately, its efficacy is dis-
cussed because most patients remain with some degree
of angina. Major limitation of TMR is that the clinical
benefit is partly lost in the long term follow up suggesting
that the improvement may be transient, although recent
studies have reported the effectiveness of TMR up to five
years (6). An important question is whether the effec-
tiveness of TMR can be increased and maintained by a
better understanding and exploitation of its mechanism
of action. Our experience is very limited but the case re-
port presented supports the hypothesis of benefits in long
term follow up: patient had not longer angina altought
in the recent period had mild dispnea. Moreover, the im-
ages show that TMR could induce in long term follow
up a reguardable angiogenesis that may explain its ben-
efits (7-11).  
The main advantages of TMR compared to CABG
surgery are: 
- mini-invasive surgery using skin incision less than
10 cm or even thoracoscopic; 
- does not need extracorporeal circulation and car-
diac arrest; 
- early extubation and hospital stay limited to a few
days; 
- possibility of implementing the procedure in cas-
es of severe carotid artery disease, or malignancy
with less risk to the patient; 
- recovery of the patient faster. 
We learned something about TMR procedure dur-
ing our experience: first of all, the risk of malignat ar-
rhythmias is considerable so that a continuous intravenous
infusion with Xilocaina is mandatory. It is recommended
to prevent excessive body cooling during the procedure
using a heating system. In case of severe impairment of
left ventricular function or for instable patients, could
be useful preoperative IABP implantation in order to re-
duce left ventricular afterload improving coronary per-
fusion. Moreover, channels creation should be respon-
sible of myocardial edema: so that we recommended the
use of steroids for the 24-36 hour after procedure in or-
der to prevent edema and the risk of myocardial dys-
function.
Conclusion
Our experience confirms that TMR is a safe and fea-
sible procedure and it offers a therapeutic solution in
case of untreatable angina. Moreover, it could be a hy-
brid approach for patients undergoing CABGs in case
of absence of vessels suitable for surgical approach in lim-
ited areas of the heart. Finally, the costs for surgical ap-
proach and patients management are limited and this
makes TMR an interesting approach for patients with
untreatable angina.
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